N. B. Ackerman, W. M. Lien, E. S. Kondi, and N. A. Silverman, The blood supply of experimental liver metastases. I. The distribution of hepatic artery and portal vein blood to " small " and " large " tumors, Surgery, pp.66-1067, 1969.

R. Alberto, R. Schibli, R. Waibel, U. Abram, and A. P. Schubiger, Basic aqueous chemistry of [M(OH 2 ) 3 (CO) 3 ] + (M=Re, Tc) directed towards radiopharmaceutical application, Coord. Chem. Rev, pp.190-192901, 1999.

R. Alberto, The particular role of radiopharmacy within bioorganometallic chemistry, 2007.

R. Alberto, The Chemistry of Technetium-Water Complexes within the Manganese Triad: Challenges and Perspectives, European Journal of Inorganic Chemistry, vol.99, issue.1, pp.21-31, 2009.
DOI : 10.1002/ejic.200800909

R. A. Al-mufti, R. B. Pedley, D. Marshall, R. H. Begent, A. Hilson et al., In vitro assessment of Lipiodol-targeted radiotherapy for liver and colorectal cancer cell lines, British Journal of Cancer, vol.13, issue.11-12, pp.79-1665, 1999.
DOI : 10.1038/sj.bjc.6690266

T. Ameller, V. Marsaud, P. Legrand, R. Gref, and J. M. Renoir, In vitro andin vivo biologic evaluation of long-circulating biodegradable drug carriers loaded with the pure antiestrogen RU 58668, International Journal of Cancer, vol.8, issue.3, pp.446-454, 2003.
DOI : 10.1002/ijc.11248

T. J. Anderson, D. J. Ferguson, and G. M. Roab, Cell turnover in the ???resting??? human breast: influence of parity, contraceptive pill, age and laterality, British Journal of Cancer, vol.46, issue.3, pp.46-376, 1982.
DOI : 10.1038/bjc.1982.213

T. Andre, E. Chastre, L. Kotelevets, J. C. Vaillant, C. Louvet et al., Tumoral angiogenesis: Physiopathology, prognostic value and therapeutic perspectives, Rev. Med. Interne, issue.12, pp.19-904, 1998.

J. H. Anolik, C. M. Klinge, R. A. Bambara, and R. Hilf, Differential impact of flanking sequences on estradiol- vs 4-hydroxytamoxifen-liganded estrogen receptor binding to estrogen responsive element DNA, The Journal of Steroid Biochemistry and Molecular Biology, vol.46, issue.6, pp.713-730, 1993.
DOI : 10.1016/0960-0760(93)90312-K

V. Ardison, Evaluation des nouveaux radiopharmaceutiques, Thèse de doctorat, 2006.

J. L. Arriza, C. Weinberger, G. Cerelli, T. M. Glaser, B. L. Handelin et al., Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor, Science, vol.237, issue.4812, pp.268-275, 1987.
DOI : 10.1126/science.3037703

A. R. Baker, D. P. Mcdonnell, M. Hughes, T. M. Crisp, D. J. Mangelsdorf et al., Cloning and expression of full-length cDNA encoding human vitamin D receptor., Proceedings of the National Academy of Sciences, vol.85, issue.10, pp.3294-3298, 1988.
DOI : 10.1073/pnas.85.10.3294

V. Beral, Breast cancer and hormone-replacement therapy: the Million Women Study, The Lancet, vol.362, issue.9392, pp.419-427, 2003.
DOI : 10.1016/S0140-6736(03)14596-5

A. Bélanger, G. Pelletier, F. Labrie, O. Barbier, and S. Chouinard, Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans, Trends in Endocrinology & Metabolism, vol.14, issue.10, p.473, 2003.
DOI : 10.1016/j.tem.2003.10.005

C. Biot, C. Glorian, L. A. Macièjewski, and J. S. Brocard, Synthesis and Antimalarial Activity in Vitro and in Vivo of a New Ferrocene???Chloroquine Analogue, Journal of Medicinal Chemistry, vol.40, issue.23, pp.3715-3718, 1997.
DOI : 10.1021/jm970401y

J. L. Borgna and H. Rochefort, Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues, J. Biol. Chem, vol.256, pp.859-868, 1981.

N. Boucheau and C. Myers, Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment, Breast Cancer Res, vol.5, issue.3, pp.140-146, 2003.

W. Bourguet, M. Ruff, P. Chambon, H. Gronemeyer, and D. Moras, Crystal structure of the ligand-binding domain of the human nuclear receptor RXR alpha, Nature, issue.6530, pp.375-377, 1995.

W. Bourguet, P. Germain, and H. Gronemeyer, Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications, Trends in Pharmacological Sciences, vol.21, issue.10, p.381, 2000.
DOI : 10.1016/S0165-6147(00)01548-0

F. Bray, R. Sankila, J. Ferlay, and D. M. Parkin, Estimates of cancer incidence and mortality in Europe in 1995, European Journal of Cancer, vol.38, issue.1, pp.99-166, 2002.
DOI : 10.1016/S0959-8049(01)00350-1

B. Brisken, Hormonal control of alveolar development and its implications for Breast Carcinogenesis, Journal of Mammary Gland Biology and Neoplasia, vol.7, issue.1, pp.39-48, 2002.
DOI : 10.1023/A:1015718406329

A. M. Brzozowski, A. C. Pike, Z. Dauter, R. E. Hubbard, T. Bonn et al., Molecular basis of agonism and antagonism in the oestrogen receptor, Nature, vol.389, issue.6652, pp.753-758, 1997.
DOI : 10.1038/39645

J. R. Buscombe and A. Padhy, Treatment of hepatocellular carcinoma: a pivotal role for nuclear medicine?, Nuclear Medicine Communications, vol.22, issue.2, p.119, 2001.
DOI : 10.1097/00006231-200102000-00001

A. Burger and D. J. Abraham, Burger's medicinal chemistry and drug discovery, 2003.

W. F. Carlson, J. A. Katzenellenbogen, H. Spies, and B. Johannsen, Synthesis and binding affinities of a new 17a-substituted estradiol-rhenium "n+1" mixed-ligand and thioether-carbonyl complexes, Steroids, vol.63, pp.665-671, 1998.

M. G. Catelli, N. Binart, I. Jung-testas, J. M. Renoir, E. E. Baulieu et al., The common 90-kd protein component of non-transformed '8S' steroid receptors is a heat-shock protein, Embo J, vol.4, pp.3131-3135, 1985.

M. Campbell-thompson, I. J. Lynch, and B. Bhardwaj, Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer, Cancer Res, vol.61, pp.632-640, 2001.

C. Chesne, G. Leclercq, P. Pointeau, and H. Patin, Synthesis and biological studies of aminoestradiol-platinum (II) conjugates, Eur. J. Med. Chem, vol.21, pp.321-327, 1986.

M. E. Chevreul, Examen des graisses d'homme, de mou-ton, de boeuf, de jaguar et d'oie, Ann. Chim. Phys, vol.2, pp.339-372, 1816.

F. Claessens, G. Verrijdt, E. Schoenmakers, A. Haelens, B. Peeters et al., Selective DNA binding by the androgen receptor as a mechanism for hormone-specific gene regulation, The Journal of Steroid Biochemistry and Molecular Biology, vol.76, issue.1-5, pp.76-99, 2001.
DOI : 10.1016/S0960-0760(00)00154-0

R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar, Cellular and molecular pharmacology of antiestrogen action and resistance, Pharmacol. Rev, vol.53, pp.25-71, 2001.

E. Clavel-chapelon, Cumulative number of menstrual cycles and breast cancer risk: Results from the E3N cohort study of French women, Cancer Causes and Control, vol.13, issue.9, pp.831-838, 2002.
DOI : 10.1023/A:1020684821837
URL : https://hal.archives-ouvertes.fr/inserm-00136439

J. A. Clemens, D. R. Bennett, L. J. Black, and C. D. Jones, Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels, Life Sciences, vol.32, issue.25, pp.2869-2875, 1983.
DOI : 10.1016/0024-3205(83)90323-5

H. H. Coenen, J. Mertens, and B. Mazière, Radioionidation reactions for pharmaceuticals, compendium for effective synthesis strategies, 2006.

C. Bennink and H. J. , Are all estrogens the same?, Maturitas, vol.47, issue.4, pp.269-275, 2004.
DOI : 10.1016/j.maturitas.2003.11.009

S. M. Cowley, S. Hoare, S. Mosselman, and M. G. Parker, Estrogen receptor alpha and beta form heterodimers on DNA, J Biol Chem, vol.272, 1997.

R. H. Crabtree, The organometallic chemistry of the transition elements, 2005.

C. R. Culy, D. Clemett, and L. R. Wiseman, Oxaliplatin, Drugs, vol.71, issue.3, pp.895-924, 2000.
DOI : 10.2165/00003495-200060040-00005

O. Gandolfi, J. Blum, and F. Mandelbaumshavit, Antitumor steroidal-cis-platinum(II)-o-catecholato conjugates: preliminary evaluation on breast cancer MCF-7 cells, Inorganica Chimica Acta, vol.91, issue.4, pp.257-261, 1984.
DOI : 10.1016/S0020-1693(00)81847-2

W. Gao, J. D. Kearbey, V. A. Nair, K. Chung, A. F. Parlow et al., Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 52-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia, Endocrinology, pp.145-5420, 2004.

P. Bourguet, Development of 99m Tc labelled Lipiodol: biodistribution following injection into the hepatic artery of the healthy pig, Nucl. Med. Com, vol.25, issue.3, pp.291-298, 2004.

S. Gauthier, J. Mailhot, and F. Labrie, )-4-Hydroxytoremifene via McMurry Reaction, The Journal of Organic Chemistry, vol.61, issue.11, pp.3890-3893, 1996.
DOI : 10.1021/jo952279l

L. S. Goodman, J. G. Hardman, L. E. Limbird, and A. G. Gilman, Goodman and Gilman's the pharmacological basis of therapeutics McGraw-Hill Medical Pub. Division: New Comparative toxicity of [3]ferrocenophane and ferrocene moieties on breast cancer cells, Tetrahedron Lett, vol.10, issue.51, pp.118-120, 2001.

M. V. Govindan, M. Devic, S. Green, H. Gronemeyer, and P. Chambon, Cloning of the human glucocorticoid receptor cDNA, Nucleic Acids Research, vol.13, issue.23, pp.8293-8304, 1985.
DOI : 10.1093/nar/13.23.8293

G. Grenier, G. Bérubé, and C. Gicquaud, Effects of New Triphenylethylene Platinum(II) Complexes on the Interaction with Phosphatidylcholine Liposomes., CHEMICAL & PHARMACEUTICAL BULLETIN, vol.46, issue.9, p.1480, 1998.
DOI : 10.1248/cpb.46.1480

R. Gust, H. Schönenberger, U. Klement, and K. J. Range, Aqua[1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine]sulfatoplatinum(II) Complexes with Variable Substituents in the 2-Phenyl Ring, II: Correlation of Molecular Structure and Estrogenic Activity of Breast and Prostate Cancer Inhibiting [erythro-1-(2,6-Dichloro-4-hydroxyphenyl)-2-(2-halo-4-hydroxyphenyl)ethylenediamine]platinum(II) Complexes, Archiv der Pharmazie, vol.97, issue.12, pp.967-976, 1993.
DOI : 10.1002/ardp.19933261211

T. Hara, N. Kosaka, and H. Kishi, Development of 18 F-Fluoroethylcholine for Cancer Imaging with PET: Synthesis, Biochemistry, and Prostate Cancer Imaging, J. Nucl. Med, vol.43, pp.187-199, 2002.

A. Haelens, G. Verrijdt, L. Callewaert, V. Christiaens, K. Schauwaers et al., DNA recognition by the androgen receptor: evidence for an alternative DNA-dependent dimerization, and an active role of sequences flanking the response element on transactivation, Biochemical Journal, vol.369, issue.1, pp.369-141, 2003.
DOI : 10.1042/bj20020912

M. G. Harris, S. G. Coleman, D. Faulds, and P. Chrisp, Nilutamide, Drugs & Aging, vol.3, issue.1, pp.9-25, 1993.
DOI : 10.2165/00002512-199303010-00002

B. He, J. T. Minges, L. W. Lee, and E. M. Wilson, The FXXLF Motif Mediates Androgen Receptor-specific Interactions with Coregulators, Journal of Biological Chemistry, vol.277, issue.12, p.10226, 2002.
DOI : 10.1074/jbc.M111975200

D. M. Heery, E. Kalkhoven, S. Hoare, and M. G. Parker, A signature motif in transcriptional co-activators mediates binding to nuclear receptors, Nature, vol.387, p.733, 1997.

C. A. Heinlein and C. Chang, Androgen Receptor (AR) Coregulators: An Overview, Endocrine Reviews, vol.23, issue.2, p.175, 2002.
DOI : 10.1210/edrv.23.2.0460

E. H. Hillard, F. C. De-abreu, D. C. Ferreira, G. Jaouen, M. O. Goulart et al., Electrochemical parameters and techniques in drug development with an emphasis on quinines and related compounds, Chem. Commun, vol.23, pp.2612-2628, 2008.

H. Hiroi, S. Inoue, T. Watanabe, W. Goto, A. Orimo et al., Differential immunolocalization of estrogen receptor alpha and beta in rat ovary and uterus, Journal of Molecular Endocrinology, vol.22, issue.1, pp.37-44, 1999.
DOI : 10.1677/jme.0.0220037

P. Prostate-cancer and . Bioprobes, Synthesis of [ 18 F]-radiolabeled hydroxyflutamide derivatives, Bioorg. Med. Chem, vol.13, issue.8, pp.6195-6205

M. A. Jakupec, M. Galanski, and B. K. Keppler, Tumour-inhibiting platinum complexes???state of the art and future perspectives, Rev. Physiol. Biochem. Pharmacol, vol.146, pp.1-53, 2003.
DOI : 10.1007/s10254-002-0001-x

G. Jaouen, S. Top, A. Vessières, G. Leclercq, J. Quivy et al., The studies of an organometallic antioestrogens and their antiproliferative effects, C. R. Acad.Sci, pp.89-93, 2000.

G. Jaouen, S. Top, A. Vessières, P. Pigeon, G. Leclerc et al., First antioestrogen in the cyclopentadienyl rhenium tricarbonyl series. Synthesis and study of antiproliferative effects, Chem. Commun, pp.383-384, 2001.
URL : https://hal.archives-ouvertes.fr/hal-01230409

G. Jaouen, S. Top, A. Vessières, G. Leclercq, and M. J. Mcglinchey, The First Organometallic Selective Estrogen Receptor Modulators (SERMs) and Their Relevance to Breast Cancer, Current Medicinal Chemistry, vol.11, issue.18, p.2505, 2004.
DOI : 10.2174/0929867043364487

J. M. Jeltsch, Z. Krozowski, C. Quirin-stricker, H. Gronemeyer, R. J. Simpson et al., Cloning of the chicken progesterone receptor., Proceedings of the National Academy of Sciences, vol.83, issue.15, pp.5424-5428, 1986.
DOI : 10.1073/pnas.83.15.5424

S. R. Johnston, Acquired tamoxifen resistance in human breast cancer???potential mechanisms and clinical implications, Anti-Cancer Drugs, vol.8, issue.10, pp.911-930, 1997.
DOI : 10.1097/00001813-199711000-00002

S. D. Jonson, T. A. Bonasera, F. Dehdashti, M. E. Cristel, J. A. Katzenellenbogen et al., Comparative breast tumor imaging and comparative in vitro metabolism of 16??-[18F]Fluoroestradiol-17?? and 16??-[18f]fluoromoxestrol in isolated hepatocytes, Nuclear Medicine and Biology, vol.26, issue.1, pp.123-153, 1999.
DOI : 10.1016/S0969-8051(98)00079-1

V. C. Jordan, Alternate antiestrogens and approaches to the prevention of breast cancer, Journal of Cellular Biochemistry, vol.50, issue.S22, pp.51-57, 1995.
DOI : 10.1002/jcb.240590808

V. C. Jordan, Tamoxifen for the treatment and prevention of breast cancer, 1999.

V. C. Jordan, J. M. Schafer, A. S. Levenson, H. Liu, K. M. Pease et al., Molecular classification of estrogens Advances in Cancer Research, pp.6619-6623, 2001.

V. C. Jordan, Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 1. Receptor Interactions, Journal of Medicinal Chemistry, vol.46, issue.6, pp.883-908, 2003.
DOI : 10.1021/jm020449y

V. C. Jordan, Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents, J. Med. Chem, issue.7, pp.46-1081, 2003.
DOI : 10.1021/jm020449y

S. Jurisson and J. D. Lydon, Potential Technetium Small Molecule Radiopharmaceuticals, Chemical Reviews, vol.99, issue.9, pp.2205-2218, 1999.
DOI : 10.1021/cr980435t

Z. Kan, K. Ivancev, A. Lunderquist, P. A. Mccuskey, K. C. Wright et al., In vivo microscopy of hepatic tumors in animal models: a dynamic investigation of blood supply to hepatic metastases., Radiology, vol.187, issue.3, pp.621-629, 1993.
DOI : 10.1148/radiology.187.3.8497606

Z. Kan, Dynamic study of iodized oil in the liver and blood supply to hepatic tumors, 1996.

R. Karl, T. Gust, M. R. Spruss, H. Schneider, J. Schönenberger et al., Ring-substituted [1,2-bis(4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) complexes: compounds with a selective effect on the hormone-dependent mammary carcinoma, Journal of Medicinal Chemistry, vol.31, issue.1, pp.72-83, 1988.
DOI : 10.1021/jm00396a012

B. M. Karlson, A. M. Lofberg, L. E. Lorelius, G. Jacobson, and U. Haglund, Intraarterial chemoembolisation with lipiodol and epirubicin in hepatocellular cancer--improved survival in some patients?, Ann. Chir.Gynaecol, vol.88, p.264, 1999.

J. A. Katzenellenbogen, S. G. Senderoff, K. D. Mcelvany, . H. O-'brien-jr, and M. J. Welch, 16 1-[ 77 Br]Bromoestradiol-17ß: A High Specific-Activity, Gamma-Emitting Tracer with Uptake in Rat Uterus and Induced Mammary Tumors, J Nucl Med, vol.22, p.42, 1981.

J. A. Katzenellenbogen, K. D. Mcelvany, S. G. Senderoff, K. E. Carlson, S. W. Landvatter et al., 16 2-[ 77 Br]Bromo-11ß-methoxyestradiol-17ß: A Gamma-Emitting Estrogen Imaging Agent with High Uptake and Retention by Target Organs, J Nucl Med, vol.23, p.411, 1982.

B. Katchen and S. Buxbaum, Disposition of a New, Nonsteroid, Antiandrogen, ??,??,??-Trifluoro-2-methyl-4???-nitro-m-propionotoluidide (Flutamide), in Men Following a single Oral 200 mg Dose, The Journal of Clinical Endocrinology & Metabolism, vol.41, issue.2, pp.373-379, 1975.
DOI : 10.1210/jcem-41-2-373

J. Kealy and P. L. Pauson, A New Type of Organo-Iron Compound, Nature, vol.165, issue.4285, pp.168-1039, 1951.
DOI : 10.1038/1681039b0

J. C. Keen and N. E. Davidson, The biology of breast carcinoma, Cancer, vol.49, issue.S3, pp.825-833, 2003.
DOI : 10.1002/cncr.11126

C. M. Klinge, Estrogen receptor interaction with co-activators and co-repressors???, Steroids, vol.65, issue.5, 2000.
DOI : 10.1016/S0039-128X(99)00107-5

H. Koch, Flutamide?A new non-steroidal anti-androgen, Drugs of Today, vol.20, p.561, 1984.

G. J. Kolvenbag and G. R. Blackledge, Worldwide activity and safety of bicalutamide: a summary review, Urology, vol.47, issue.1, pp.47-70, 1996.
DOI : 10.1016/S0090-4295(96)80012-4

M. Kos, G. Reid, S. Denger, and F. Gannon, Minireview: Genomic Organization of the Human ER?? Gene Promoter Region, Molecular Endocrinology, vol.15, issue.12, 2001.
DOI : 10.1210/me.15.12.2057

P. Köpf-maier, Complexes of metals other than platinum as antitumour agents, Eur, 1994.

P. Köpf-maier and H. Köpf, Non-platinum group metal antitumor agents. History, current status, and perspectives, Chemical Reviews, vol.87, issue.5, p.1137, 1987.
DOI : 10.1021/cr00081a012

V. Krishnan, H. Heath, and H. U. Bryant, Mechanism of action of estrogens and selective estrogen receptor modulators, Vitam. Horm, vol.60, pp.123-147, 2000.
DOI : 10.1016/S0083-6729(00)60018-3

J. M. Kuhn, T. Billebaud, H. Navratil, A. Moulonguet, J. Friet et al., Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). Engl, J. Med, vol.321, p.413, 1989.

G. G. Kuiper, E. Enmark, M. Pelto-huikko, S. Nilsson, and J. A. Gustafsson, Cloning of a novel receptor expressed in rat prostate and ovary., Proceedings of the National Academy of Sciences, vol.93, issue.12, pp.5925-5930, 1996.
DOI : 10.1073/pnas.93.12.5925

G. G. Kuiper, B. Carlsson, K. Grandien, E. Enmark, J. Haggblad et al., Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta, Endocrinology, vol.138, pp.863-870, 1997.

V. Kumar and P. Chambon, The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer, Cell, vol.55, issue.1, pp.145-156, 1988.
DOI : 10.1016/0092-8674(88)90017-7

D. Kuntschke, M. Wenzel, and P. Schulze, New [99mTc]-cytectrene amine compounds as specific brain imaging agents, Journal of Labelled Compounds and Radiopharmaceuticals, vol.30, issue.2, pp.193-203, 1995.
DOI : 10.1002/jlcr.2580360212

F. Labrie, Mechanism of action and pure antiandrogenic properties of flutamide, Cancer, vol.32, issue.S12, pp.72-3816, 1993.
DOI : 10.1002/1097-0142(19931215)72:12+<3816::AID-CNCR2820721711>3.0.CO;2-3

N. Laflamme, R. E. Nappi, G. Drolet, C. Labrie, and S. Rivest, Expression and neuropeptidergic characterization of estrogen receptors (ER? and ER?) throughout the rat brain: Anatomical evidence of distinct roles of each subtype, Journal of Neurobiology, vol.93, issue.3, pp.357-378, 1998.
DOI : 10.1002/(SICI)1097-4695(19980905)36:3<357::AID-NEU5>3.0.CO;2-V

V. Laudet, C. Hanni, J. Coll, F. Catzeflis, and D. Stehelin, Evolution of the nuclear receptor gene superfamily, Embo J, vol.11, pp.1003-1013, 1992.

E. Leygue, H. Dotzlaw, P. H. Watson, and L. C. Murphy, Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis, Cancer Res, vol.58, pp.3197-3201, 1998.

J. S. Lewis and V. C. Jordan, Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance Mutation Research/Fundamental and molecular mechanisms of mustagenesis, pp.247-263, 2005.

G. Lin, A. Lunderquist, I. Hagerstrand, and E. Boijsen, Postmortem examination of the blood supply and vascular pattern of small liver metastases in man, Surgery, pp.96-517, 1984.

B. Lippert, Cisplatin: Chemistry and Biochemistry of a leading Anticancer Drug, 1999.
DOI : 10.1002/9783906390420

C. L. Liu and S. T. Fan, Nonresectional therapies for hepatocellular carcinoma, The American Journal of Surgery, vol.173, issue.4, p.358, 1997.
DOI : 10.1016/S0002-9610(96)00384-4

R. V. Lloyd, S. Vidal, E. Horvath, K. Kovacs, and B. Scheithauer, Angiogenesis in normal and neoplastic pituitary tissues, Microscopy Research and Technique, vol.19, issue.2, pp.244-250, 2003.
DOI : 10.1002/jemt.10263

L. G. Luyt, H. M. Bigott, M. J. Welch, and J. A. Katzenellenbogen, 7alpha-and 17alpha- substituted estrogens containing tridentate tricarbonyl rhenium/technetium complexes: synthesis of estrogen receptor imaging agents and evaluation using microPET with technetium-94m, Bioorg Med Chem, issue.23, pp.11-4977, 2003.

B. Lytton, PROSTATE CANCER:, The Journal of Urology, vol.165, pp.1859-1862, 2001.
DOI : 10.1097/00005392-200106000-00004

I. Macgregor and V. C. Jordan, Basic guide to the mechanisms of antiestrogen action, Pharmacol. Rev, vol.50, pp.151-196, 1998.

R. A. Magarian, L. B. Overacre, S. Singh, and K. L. Meyer, The medicinal chemistry of nonsteroidal antiestrogens: a review, Curr. Med. Chem, vol.1, p.61, 1994.

S. Maillard, T. Ameller, T. Gauduchon, A. Googelet, F. Gouilleux et al., Innovative drug delivery nanosystems improve the anti-tumor activity in vitro and in vivo of anti-estrogens in human breast cancer and multiple myeloma, The Journal of Steroid Biochemistry and Molecular Biology, vol.94, issue.1-3, pp.111-121, 2005.
DOI : 10.1016/j.jsbmb.2004.12.023
URL : https://hal.archives-ouvertes.fr/hal-00389005

S. Marivoet, P. Van-dijck, G. Verhoeven, and W. Heyns, Interaction of the 90-kDa heat shock protein with native and in vitro translated androgen receptor and receptor fragments, Molecular and Cellular Endocrinology, vol.88, issue.1-3, pp.165-174, 1992.
DOI : 10.1016/0303-7207(92)90021-W

R. W. Mason, K. Mcgrouther, P. R. Ranatunge-bandarage, B. H. Robinson, and . Simpson, Toxicology and antitumour activity of ferrocenylamines and platinum derivatives, Applied Organometallic Chemistry, vol.55, issue.3, p.163, 1999.
DOI : 10.1002/(SICI)1099-0739(199903)13:3<163::AID-AOC821>3.0.CO;2-K

S. Masi, S. Top, L. Boubeker, G. Jaouen, S. Mundwiler et al., Direct synthesis of tricarbonyl(cyclopentadienyl)rhenium and tricarbonyl(cyclopentadienyl )technetium units from ferrocenyl moieties. preparation of17alpha- ethynylestradiol derivatives bearing a tricarbonyl(cyclopentadienyl)technetium group, Eur. J. Inorg. Chem, vol.10, pp.2013-2017, 2004.

D. P. Mcdonnell and J. D. Norris, Connections and Regulation of the Human Estrogen Receptor, Science, vol.296, issue.5573, pp.1642-1644, 2002.
DOI : 10.1126/science.1071884

K. D. Mcelvany, J. A. Katzenellenbogen, K. E. Shafer, B. A. Siegel, S. G. Senderoff et al., 16 2-[ 77 Br]Bromoestradiol: Dosimetry and Preliminary Clinical Studies, J Nucl Med, vol.23, pp.425-455, 1982.

N. J. Mckenna, R. B. Lanz, and B. W. O-'malley, Nuclear Receptor Coregulators: Cellular and Molecular Biology, Endocrine Reviews, vol.20, issue.3, pp.321-344, 1999.
DOI : 10.1210/er.20.3.321

N. J. Mckenna and B. W. O-'malley, Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators, Cell, vol.108, issue.4, pp.465-474, 2002.
DOI : 10.1016/S0092-8674(02)00641-4

D. G. Mcleod, Antiandrogenic drugs, Cancer, vol.321, issue.S3, pp.71-1046, 1993.
DOI : 10.1002/1097-0142(19930201)71:3+<1046::AID-CNCR2820711424>3.0.CO;2-M

M. J. Meegan and D. G. Lloyd, Advances in the Science of Estrogen Receptor Modulation, Current Medicinal Chemistry, vol.10, issue.3, pp.181-210, 2003.
DOI : 10.2174/0929867033368501

F. Ménégoz, R. J. Black, P. Arveux, V. Magne, J. Ferlay et al., Cancer incidence and mortality in France in 1975???95, European Journal of Cancer Prevention, vol.6, issue.5, pp.442-446, 1997.
DOI : 10.1097/00008469-199710000-00005

L. P. Menasce, G. R. White, C. J. Harrison, and J. M. Boyle, Localization of the Estrogen Receptor Locus (ESR) to Chromosome 6q25.1 by FISH and a Simple Post-FISH Banding Technique, Genomics, vol.17, issue.1, pp.263-265, 1993.
DOI : 10.1006/geno.1993.1320

P. Michel, O. Goria, and G. Riachi, Carcinome hépatocellulaire : alcoolisation, radiofréquence, chimio-embolisation, iode radioactif : quel gain réel de survie ? = Hepatocellular carcinoma : alcohol treatment, radiofrequency,chimio-embolization, radioactivity iodine :what real gain of survival, La Lettre de l'Hépato-Gastroentérologue, p.30, 2001.

W. L. Miller, Molecular Biology of Steroid Hormone Synthesis*, Endocrine Reviews, vol.9, issue.3, pp.295-318, 1988.
DOI : 10.1210/edrv-9-3-295

C. P. Miller, M. D. Collini, B. D. Tran, H. A. Harris, Y. P. Kharode et al., Design, Synthesis, and Preclinical Characterization of Novel, Highly Selective Indole Estrogens, Journal of Medicinal Chemistry, vol.44, issue.11, pp.1654-1657, 2001.
DOI : 10.1021/jm010086m

F. Minutolo and J. A. Katzenellenbogen, -Cyclopentadienyltricarbonylrhenium Complexes:?? Scope, Limitations, and Mechanistic Interpretations, Organometallics, vol.18, issue.13, pp.2519-2530, 1999.
DOI : 10.1021/om990128t
URL : https://hal.archives-ouvertes.fr/hal-00663057

M. Moguilewsky and M. M. Bouton, How the study of the biological activities of antiandrogens can be oriented towards the clinic, Journal of Steroid Biochemistry, vol.31, issue.4, pp.31-699, 1988.
DOI : 10.1016/0022-4731(88)90021-0

J. E. Mortimer, F. Dehdashti, B. A. Siegel, J. A. Katzenellenbogen, P. Fracasso et al., Positron emission tomography with 2-18F. Fluoro-2-deoxy-D-glucose and 16alpha-18F. fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy, Clin Cancer Res, vol.2, pp.933-942, 1996.

S. Mosselman, J. Polman, and R. Dijkema, ER??: Identification and characterization of a novel human estrogen receptor, FEBS Letters, vol.10, issue.1, pp.49-53, 1996.
DOI : 10.1016/0014-5793(96)00782-X

A. O. Mueck, H. Seeger, and T. H. Lippert, Estradiol metabolism and malignant disease, Maturitas, vol.43, issue.1, pp.1-10, 2002.
DOI : 10.1016/S0378-5122(02)00141-X

C. Müller, P. A. Schubiger, and R. Schibli, Isostructural folate conjugates radiolabeled with the matched pair 99mTc/188Re: a potential strategy for diagnosis and therapy of folate receptor-positive tumors, Nuclear Medicine and Biology, vol.34, issue.6, pp.595-601, 2007.
DOI : 10.1016/j.nucmedbio.2007.05.011

V. C. Musey, D. C. Collins, D. R. Brogan, V. R. Santos, P. I. Musey et al., Long Term Effects of a First Pregnancy on the Hormonal Environment: Estrogens and Androgens*, The Journal of Clinical Endocrinology & Metabolism, vol.64, issue.1, pp.111-118, 1987.
DOI : 10.1210/jcem-64-1-111

Y. Hosogi, Hepatocellular carcinoma detected by iodized oil. Use of anticancer agents, Radiology, vol.154, p.25, 1985.

K. Okuda, H. Musha, and T. Yamasaki, Angiographic Demonstration of Intrahepatic Arterio-Portal Anastomoses in Hepatocellular Carcinoma, Radiology, vol.122, issue.1, p.53, 1977.
DOI : 10.1148/122.1.53

H. Olsson, Tumor biology of a Breast Cancer at least partly reflects the biology of the tissue/epithelial cell of origin at the time of initiation ?a hypothesis, J. Steroid Biochem. Mol, 2000.

C. K. Osborne, Tamoxifen in the treatment of breast cancer, N. Engl. J. Med, vol.3398, pp.1609-1618, 1998.

E. E. Parent, C. Jenks, T. Sharp, M. J. Welch, and J. A. Katzenellenbogen, Synthesis and biological evaluation of a nonsteroidal bromine-76-labeled androgen receptor ligand, 2006.

E. E. Parent, C. S. Dence, C. Jenks, T. L. Sharp, M. J. Welch et al., Synthesis and Biological Evaluation of, 2007.

. Br and . Bromobicalutamide, 4-[ 76 Br]Bromo-thiobicalutamide as Non-Steroidal Androgens for Prostate Cancer Imaging, J. Med. Chem, vol.50, pp.1028-1040

O. Payen, Synthèse d'anti-androgènes organométalliques non stéroïdiens et application au traitement du cancer de la prostate, Thèse de doctorat, 2007.

M. Petkovich, N. J. Brand, A. Krust, and P. Chambon, A human retinoic acid receptor which belongs to the family of nuclear receptors, Nature, vol.330, issue.6147, pp.444-50, 1987.
DOI : 10.1038/330444a0

P. Pigeon, S. Top, O. Zekri, E. A. Hillard, A. Vessières et al., The replacement of a phenol group by an aniline or acetanilide group enhances the cytotoxicity of 2-ferrocenyl-1,1-diphenyl-but-l-ene compounds against breast cancer cells, Journal of Organometallic Chemistry, vol.694, issue.6, pp.895-901, 2009.
DOI : 10.1016/j.jorganchem.2008.11.035

C. Amatore, J. Zakrzewski, and G. Jaouen, A [3]ferrocenophane polyphenol showing a remarkable antiproliferative activity on breast and prostate cancer cell lines.8 8 8 8J, Med. Chem, vol.52, issue.8, pp.4964-4967, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00448988

K. Polyak, On the birth of breast cancer, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1552, issue.1, pp.1-13, 2001.
DOI : 10.1016/S0304-419X(01)00029-4

S. N. Reske, N. M. Blumstein, B. Neumaier, H. W. Gottfried, F. Finsterbusch et al., Imaging Prostate Cancer with 11 C-Choline PET/CT, J. Nucl. Med, vol.47, pp.1249-1254, 2006.

J. F. Robertson, Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective, Cancer Treatment Reviews, vol.30, issue.8, pp.695-706, 2004.
DOI : 10.1016/j.ctrv.2004.04.003

A. Roche, T. De-baere, and V. Kuoch, Que reste-t-il de la chimioembolisation h??patique?, Acta Endoscopica, vol.86, issue.5, pp.31-61, 2001.
DOI : 10.1007/BF03018017

O. W. Rokhlin, A. F. Taghiyev, N. V. Guseva, R. A. Glover, P. M. Chumakov et al., Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP, Oncogene, vol.1551, issue.45, pp.6773-6784, 2005.
DOI : 10.1038/sj.onc.1208833

Z. , K. L. Henderson, and B. E. , Androgen Metabolism and Prostate Cancer: Establishing a Model of Genetic Susceptibility, Cancer Research, vol.58, pp.4497-4504, 1998.

B. Rosenberg, L. Vancamp, J. E. Trosko, and V. H. Mansour, Platinum Compounds: a New Class of Potent Antitumour Agents, Nature, vol.34, issue.5191, pp.385-386, 1969.
DOI : 10.1038/222385a0

B. Rosenberg, L. Vancamp, and T. Krigas, Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode, Nature, vol.3, issue.4972, pp.698-699, 1965.
DOI : 10.1038/205698a0

B. Rosenberg and L. Vancamp, The successful regression of large solid sarcoma 180 tumors by platinum compounds, Cancer Res, vol.30, pp.1799-1802, 1970.

D. Russell, D. M. Berman, . J. Bryant, K. M. Cala, D. L. Davis et al., The molecular genetics of steroid 5 alpha-reductases, 1994.

J. H. Russo and J. Russo, Role of hormones in mammary cancer: initiation and progression, Journal of Mammary Gland Biology and Neoplasia, vol.3, issue.1, pp.49-61, 1998.
DOI : 10.1023/A:1018770218022

S. D. Ryder, P. M. Rizzi, E. Metivier, J. Karani, and R. Williams, Chemoembolization with lipiodol and doxorubicin : applicability in British patients with hepatocellular carcinoma, Gut, vol.388, issue.125, p.8, 1996.

K. Saatchi and U. O. Häfeli, Radiolabeling of biodegradable polymeric microspheres with [99mTC(CO)3]+ and in vivo biodistribution evaluation using microSPECT, 2009.

S. Safe, Transcriptional activation of genes by 17??-estradiol through estrogen receptor-Sp1 interactions, Vitam Horm, vol.62, pp.231-252, 2001.
DOI : 10.1016/S0083-6729(01)62006-5

M. Salomonsson, J. Haggblad, B. W. O-'malley, and G. M. Sitbon, The human estrogen receptor hormone binding domain dimerizes independently of ligand activation, The Journal of Steroid Biochemistry and Molecular Biology, vol.48, issue.5-6, pp.447-452, 1994.
DOI : 10.1016/0960-0760(94)90192-9

E. R. Sanchez, D. O. Toft, M. J. Schlesinger, and W. B. Pratt, Evidence that the 90-kDa phosphoprotein associated with the untransformed L-cell glucocorticoid receptor is a murine heat shock protein, J Biol Chem, vol.260, pp.12398-12401, 1985.

J. Sap, A. Munoz, K. Damm, Y. Goldberg, J. Ghysdael et al., The c-erb-A protein is a high-affinity receptor for thyroid hormone, Nature, vol.70, issue.6098, pp.635-640, 1986.
DOI : 10.1038/324635a0

M. Sar and F. Welsch, Differential expression of estrogen receptor-and estrogen receptor-in the rat ovary, Endocrinology, vol.140, pp.963-971, 1999.

M. Schulz, A. Schmoldt, F. Donn, and H. Becker, The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment, European Journal of Clinical Pharmacology, vol.44, issue.6, p.633, 1988.
DOI : 10.1007/BF00615229

J. W. Schwabe, L. Chapman, J. T. Fintch, and D. Rhodes, The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: How receptors discriminate between their response elements, Cell, vol.75, issue.3, pp.567-578, 1993.
DOI : 10.1016/0092-8674(93)90390-C

F. Sciarra, G. Toscano, G. Concolino, D. Silverio, and F. , Antiandrogens: Clinical applications, The Journal of Steroid Biochemistry and Molecular Biology, vol.37, issue.3, pp.349-362, 1990.
DOI : 10.1016/0960-0760(90)90484-3

B. Segnitz and U. Gehring, Subunit structure of the nonactivated human estrogen receptor., Proc.Natl. Acad.Sci. USA, pp.2179-2183, 1995.
DOI : 10.1073/pnas.92.6.2179

S. G. Senderoff, K. D. Mcelvany, K. E. Carlson, D. F. Heiman, J. A. Katzenellenbogen et al., Methodology for the synthesis and specific activity determination of 16??-[77Br]-Bromoestradiol-17 ?? and 16??-[77Br]-11 ??-methoxyestradiol-17 ??, Two estrogen receptor-binding radiopharmaceuticals, The International Journal of Applied Radiation and Isotopes, vol.33, issue.7, pp.545-51, 1982.
DOI : 10.1016/0020-708X(82)90010-2

Y. Seimbille, F. Benard, and J. E. Van-lier, Synthesis of 16a-fluoro ICI 182,780 derivatives: powerful antiestrogens to image estrogen receptor densities in breast cancer by position emission tomography, J Chem Soc Perkin Trans, vol.20, pp.2275-81, 2002.

P. L. Shaffer, A. Jivan, D. E. Dollins, F. Claessens, and D. T. Gewirth, Structural basis of androgen receptor binding to selective androgen response elements, Proceedings of the National Academy of Sciences, vol.101, issue.14, p.4758, 2004.
DOI : 10.1073/pnas.0401123101

C. L. Smith and B. W. O-'malley, Coregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators, Endocrine Reviews, vol.25, issue.1, pp.45-71, 2004.
DOI : 10.1210/er.2003-0023

J. W. Seo, C. D. , D. C. Welch, M. J. Katzenellenbogen, and J. A. , Synthesis and biodistribution of fluorine-18-labeled fluorocyclofenils for imaging the estrogen receptor, Nuclear Medicine and Biology, vol.34, issue.4, pp.345-470, 2007.
DOI : 10.1016/j.nucmedbio.2007.01.010

Y. Shang, M. Myers, and M. Brown, Formation of the Androgen Receptor Transcription Complex, Molecular Cell, vol.9, issue.3, p.601, 2002.
DOI : 10.1016/S1097-2765(02)00471-9

S. M. Singh, S. Gauthier, and F. Labrie, Androgen Receptor Antagonists (Antiandrogens) Structure-Activity Relationships, Current Medicinal Chemistry, vol.7, issue.2, p.211, 2000.
DOI : 10.2174/0929867003375371

M. B. Skaddan, F. R. Wüst, and J. A. Katzenellenbogen, Synthesis and Binding Affinities of Novel Re-Containing 7??-Substituted Estradiol Complexes:?? Models for Breast Cancer Imaging Agents, The Journal of Organic Chemistry, vol.64, issue.22, pp.8108-8121, 1999.
DOI : 10.1021/jo990641g

T. W. Spradau and J. A. Katzenellenbogen, Preparation of Cyclopentadienyltricarbonylrhenium Complexes Using a Double Ligand-Transfer Reaction, Organometallics, vol.17, issue.10, 1998.
DOI : 10.1021/om971018u

T. W. Spradau, W. B. Edwards, C. J. Anderson, M. J. Welch, and J. A. Katzenellenbogen, Synthesis and biological evaluation of tc-99m-cyclopentadienyltricarbonyltechnetium-labeled octreotide, Nuclear Medicine and Biology, vol.26, issue.1, pp.1-7, 1999.
DOI : 10.1016/S0969-8051(98)00060-2

E. H. Starling, The Chemical Correlation of the functions of the body, Lecture I, Lancet, vol.2, 1905.

H. Bunz, G. Jaouen, and G. , Synthesis, oxidation chemistry and cytotoxicity studies on ferrocene derivatives of diethylstilbestrol, Dalton trans, vol.48, pp.10871-10881, 2009.
URL : https://hal.archives-ouvertes.fr/hal-01230395

S. Top, E. B. Kaloun, A. Vessières, G. Leclercq, I. Laios et al., Tamoxifen Derivatives for Delivery of the Antitumoral (DACH)Pt Group: Selective Synthesis by McMurry Coupling, and Biochemical Behaviour, ChemBioChem, vol.4, issue.8, 2003.
DOI : 10.1002/cbic.200200550

S. Top, A. Vessières, G. Leclercq, J. Quivy, J. Tang et al., Synthesis, Biochemical Properties and Molecular Modelling Studies of Organometallic Specific Estrogen Receptor Modulators (SERMs), the Ferrocifens and Hydroxyferrocifens: Evidence for an Antiproliferative Effect of Hydroxyferrocifens on both Hormone-Dependent and Hormone-Independent Breast Cancer Cell Lines, Chemistry - A European Journal, vol.9, issue.21, pp.5223-5236, 2003.
DOI : 10.1002/chem.200305024

S. Top, A. Vessières, P. Pigeon, M. Rager, M. Huché et al., Selective Estrogen-Receptor Modulators (SERMs) in the Cyclopentadienylrhenium Tricarbonyl Series: Synthesis and Biological Behaviour, ChemBioChem, vol.33, issue.407, pp.1104-1113, 2004.
DOI : 10.1002/cbic.200400067
URL : https://hal.archives-ouvertes.fr/hal-01230404

S. Top, C. L. Thibaudeau, A. , C. E. , L. Bideau et al., Synthesis and Structure Activity Relationship of Organometallic Steroidal Androgen Derivatives, Organometallics, vol.28, issue.5, pp.1414-1424, 2009.
DOI : 10.1021/om800698y
URL : https://hal.archives-ouvertes.fr/hal-00376100

V. Giguere, Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor beta, Mol Endocrinol, vol.11, pp.353-365, 1997.

H. Tucker, J. W. Crook, and G. J. Chesterson, Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3, 1988.

H. Vanbrocklin, K. E. Carlson, J. A. Katzenellenbogen, and . M. Welch, 16.beta.-([18F]Fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors, Journal of Medicinal Chemistry, vol.36, issue.11, p.36, 1993.
DOI : 10.1021/jm00063a012

P. Van-de-velde, F. Nique, F. Bouchoux, J. Bremaud, M. C. Hameau et al., RU58, 668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice, J. Steroid Biochem. Mol, 1994.

F. Vandenbos, D. Chevallier, and J. F. Michiels, Histopathological classification of prostate cancers, ONCOLOGIE, vol.6, issue.6, pp.385-393, 2004.
DOI : 10.1007/s10269-004-0104-x

A. Venook, Treatment of hepatocellular carcinoma: too many options?, Journal of Clinical Oncology, vol.12, issue.6, p.1323, 1994.
DOI : 10.1200/JCO.1994.12.6.1323

M. Verderame, CRC handbook of hormones, vitamins and radiopaques, 1986.

A. Vessières, S. Top, W. Beck, E. A. Hillard, and G. Jaouen, Metal complex SERMs (selective oestrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferative effects, Dalton Trans., vol.41, issue.47, pp.529-541, 2006.
DOI : 10.1039/B509984F

A. Vessières, D. Spera, S. Top, B. Misterkiewicz, I. M. Heldt et al., The Presence of a Ferrocenyl Unit on an Estrogenic Molecule is Not Always Sufficient to Generate in???vitro Cytotoxicity, ChemMedChem, vol.33, issue.11, pp.1275-1281, 2006.
DOI : 10.1002/cmdc.200600176

V. Angerer, E. Prekajac, and J. , 2-(Hydroxyphenyl)indoles: a new class of mammary tumor-inhibiting compounds, Journal of Medicinal Chemistry, vol.26, issue.1, pp.113-116, 1983.
DOI : 10.1021/jm00355a024

V. Angerer, E. Knebel, N. Kager, M. Ganss, and B. , 1-(Aminoalkyl)-2-phenylindoles as novel pure estrogen antagonists, Journal of Medicinal Chemistry, vol.33, issue.9, pp.2635-2640, 1990.
DOI : 10.1021/jm00171a045

V. Angerer and E. , Platinum complexes with specific activity against hormone dependent tumors, p.8, 1993.

A. E. Wakeling, B. J. Furr, A. T. Glen, and L. R. Hughes, Receptor binding and biological activity of steroidal and nonsteroidal antiandrogens, Journal of Steroid Biochemistry, vol.15, p.355, 1981.
DOI : 10.1016/0022-4731(81)90297-1

A. E. Wakeling, M. Dukes, and J. Bowler, A potent specific pure antiestrogen with clinical potential, Cancer Res, vol.51, pp.3867-3873, 1991.

A. E. Wakeling and J. Bowler, ICI 182,780, a new antiestrogen with clinical potential, J, 1992.

P. Walter, S. Green, G. Greene, A. Krust, J. M. Bornert et al., Cloning of the human estrogen receptor cDNA., ProcNatl Acad Sci U S A, pp.7889-7893, 1985.
DOI : 10.1073/pnas.82.23.7889

H. Whang, G. A. Peters, X. Zeng, M. Tang, W. Ip et al., Yeast Two-hybrid System Demonstrates That Estrogen Receptor Dimerization Is Ligand-dependent in Vivo, Journal of Biological Chemistry, vol.270, issue.40, pp.23322-23329, 1995.
DOI : 10.1074/jbc.270.40.23322

J. Wald, R. Alberto, K. Ortner, and L. Candreia, Aqueous One-Pot Synthesis of Derivatized Cyclopentadienyl-Tricarbonyl Complexes of99mTc with an In Situ CO Source: Application to a Serotonergic Receptor Ligand, Angewandte Chemie International Edition, vol.123, issue.16, pp.3062-3066, 2001.
DOI : 10.1002/1521-3773(20010817)40:16<3062::AID-ANIE3062>3.0.CO;2-O

A. Warnmark, E. Treuter, A. P. Wright, and J. A. Gustafsson, Activation Functions 1 and 2 of Nuclear Receptors: Molecular Strategies for Transcriptional Activation, Molecular Endocrinology, vol.17, issue.10, pp.17-1901, 2003.
DOI : 10.1210/me.2002-0384

P. Webb, G. N. Lopez, R. M. Uht, and P. J. Kushner, Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens, Mol Endocrinol, vol.9, pp.443-456, 1995.

Z. Weihua, M. Warner, and J. A. Gustafsson, Estrogen receptor beta in the prostate, Molecular and Cellular Endocrinology, vol.193, issue.1-2, pp.1-5, 2002.
DOI : 10.1016/S0303-7207(02)00089-8

S. L. Willhite, S. R. Goebel, and J. A. Scoggin, Raloxifene Provides an Alternative for Osteoporosis Prevention, Annals of Pharmacotherapy, vol.348, issue.7-8, pp.834-837, 1998.
DOI : 10.1345/aph.17335

T. M. Willson, J. D. Norris, B. L. Wagner, I. Asplin, P. Baer et al., Dissection of the Molecular Mechanism of Action of GW5638, a Novel Estrogen Receptor Ligand, Provides Insights into the Role of Estrogen Receptor in Bone, Endocrinology, vol.138, issue.9, pp.3901-3911, 1997.
DOI : 10.1210/en.138.9.3901

C. Wilkinson, M. Rosenberg, M. C. Whiting, and R. B. Woodward, Hybrid of ferrocene and fullerene, J. Am. Chem. Soc, pp.74-2125, 1952.

E. P. Winer, C. Hudis, H. J. Burstein, A. C. Wol, K. I. Pritchard et al., American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor???Positive Breast Cancer: Status Report 2004, Journal of Clinical Oncology, vol.23, issue.3, pp.619-629, 2004.
DOI : 10.1200/JCO.2005.09.121

C. I. Wong, W. R. Kelce, M. Sar, and E. M. Wilson, Androgen Receptor Antagonist versus Agonist Activities of the Fungicide Vinclozolin Relative to Hydroxyflutamide, Journal of Biological Chemistry, vol.270, issue.34, 1995.
DOI : 10.1074/jbc.270.34.19998

J. R. Wood, G. L. Greene, and A. M. Nardulli, Estrogen Response Elements Function as Allosteric Modulators of Estrogen Receptor Conformation, Molecular and Cellular Biology, vol.18, issue.4, pp.1927-1934, 1998.
DOI : 10.1128/MCB.18.4.1927

J. R. Wood, V. S. Likhite, M. A. Loven, and A. M. Nardulli, Allosteric Modulation of Estrogen Receptor Conformation by Different Estrogen Response Elements, Molecular Endocrinology, vol.15, issue.7, pp.1114-1126, 2001.
DOI : 10.1210/mend.15.7.0671

R. Wooster and B. L. Weber, Breast and ovarian cancer, N. Engl. J. Med, vol.348, pp.2339-2347, 2003.

Y. L. Wu, X. Yang, Z. Ren, D. P. Mcdonnell, J. D. Norris et al., Structural Basis for an Unexpected Mode of SERM-Mediated ER Antagonism, Molecular Cell, vol.18, issue.4, pp.413-424, 2005.
DOI : 10.1016/j.molcel.2005.04.014

J. M. Wurtz, W. Bourguet, J. P. Renaud, V. Vivat, P. Chambon et al., A canonical structure for the ligand-binding domain of nuclear receptors, Nature Structural Biology, vol.50, issue.1, p.8, 1996.
DOI : 10.1107/S0021889891004399

Y. Yumoto, K. Jinno, K. Tokuyama, Y. Araki, T. Ishimitsu et al., Hepatocellular carcino ma detected by iodized oil, Radiology, vol.1548, p.8, 1985.

F. S. Zeelen and E. W. Bergink, Cytotoxic estrogens in hormone receptive tumors, p.pp, 1980.

O. Zekri, E. H. Hillard, S. Top, A. Vessières, P. Pigeon et al., Role of aromatic substituents on the antiproliferative effects of diphenyl ferrocenyl butene compounds, Dalton Transactions, vol.27, issue.22, pp.4318-4326, 2009.
DOI : 10.1016/j.jorganchem.2008.11.035
URL : https://hal.archives-ouvertes.fr/hal-00449003

D. Zhou, T. L. Sharp, N. M. Fettig, H. Lee, J. S. Lewis et al., Evaluation of a bromine-76-labeled progestin 16??,17??-dioxolane for breast tumor imaging and radiotherapy: in vivo biodistribution and metabolic stability studies, Nuclear Medicine and Biology, vol.35, issue.6, pp.655-663, 2008.
DOI : 10.1016/j.nucmedbio.2008.05.001

B. Zivadinovic, B. Gametchu, and C. S. Watson, Membrane estrogen receptor-?? levels in MCF-7 breast cancer cells predict cAMP and proliferation responses, Breast Cancer Research, vol.277, issue.1, pp.101-112, 2005.
DOI : 10.1074/jbc.M202351200

. Si, (8) 0.0720 C(9) 0.4254(17) 0.0873(6) 0.1476(10) 0.0906 C(10) 0.4955(13) 0.1210(6) 0.2065(12) 0.0890 C(11) 0.3085(8) 0.2556(3) 0.2486(4) 0.0269 C(12) 0.2400(7) 0.3037(3) 0

. Si, O(3) -C(37) 1.357(11) N(1) -C(11) 1.351(9) N(1) -C(12) 1.421(9) C(1) -C(2) 1.413(13) C(1) -C(5) 1 C(12) -C(13) 1.399(10) C(12) -C(17) 1.389(11) C(13), ) 1.435(13) C(3) -C(4) 1.385(18) C(4) -C(5) 1.414(15) C(6) -C(7) 1.42(2) C(6) -C(10) 1.36(2) C(7) -C(8) 1.37) C(23) -C(24) 1.391(12) C(24) -C(25) 1.378(13) C(25) -C(26) 1.385(12) C(26) -C(27)) C(42) -C(44) 1.59(3) C(42) -C(45) 1, pp.413465393-413465405

. Si, 1(10) C(43) -C(42) -C(45) 110